Blood test monitoring in EGFR-mutant lung cancer treatment
Part of Cancer, Lungs & breathing clinical trials.
This study tests if regular blood tests can help guide chemotherapy treatment before surgery for people with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It aims to see if these blood tests can show how well the cancer is responding, potentially allowing doctors to adjust treatment for better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage II to IIIB non-small cell lung cancer that can be surgically removed.
- Your lung cancer has an EGFR mutation (specifically 19del or L858R).
- You are in generally good health (able to care for yourself, with good organ function).
- You have not had another cancer in the past 3 years (except certain skin or cervical cancers).
- You do not have an active infection, hepatitis B/C, or an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
This trial tests whether using a blood test (ctDNA) to guide targeted therapy after surgery can improve outcomes for patients with stage II-IIIA non-small cell lung cancer that has an EGFR mutation. If you qualify, you may receive a targeted pill (osimertinib) based on your ctDNA results.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
Hear when a new EGF-R Positive Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.